TAM June/July 2022 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
June/July 2022, Volume 30, Issue 3
Overview
- No longer available for CME credit
- Release Date: June 29, 2022
- Expiration Date: July 29, 2023
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
Learning Objectives
On completion of this activity, the learner will be able to:
- Describe the important new data presented at the 2022 Conference onRetroviruses and Opportunistic Infections and the potential clinical implications for patients in the areas of epidemiologic trends, prevention research, and basic science research in the HIV and SARS-CoV-2 pandemics
- Describe the potential treatment options for depression and bipolar depression disorders and understand how they impact those with HIV
- Describe the current epidemiology of tuberculosis, shorter regimens for its treatment, and recent advancements in treatment for patients with drug-resistant tuberculosis
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.
Intended Audience
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections.
This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
CME Information
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from July 29, 2022 to July 29, 2023. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
Dr Ances has no relevant financial affiliations to disclose. Dr Anderson has no relevant financial affiliations to disclose. Dr Letendre has had travel paid for by ViiV Healthcare. (Updated on February 14, 2022)
Inc. Dr Wilkin has served as a consultant to Merck & Co, Inc and ViiV Healthcare and has received grant support awarded to his institution from
Merck and Co, Inc and ViiV Healthcare. Dr Taylor has research grants paid to her institution pending from Gilead Sciences with no overlap between the investigator-initiated cohort of people with HIV/HBV funded by that grant and the content of the article. (Updated on February 22, 2022)
Dr Yusuf has no relevant financial affiliations to disclose. Dr Griffith has no relevant financial affiliations to disclose. Dr Agwu has no relevant financial affiliations to disclose. (Updated on May 15, 2022)
Planner/reviewer 1 has been a consultant to Antiva Biosciences, Gilead Sciences, Inc., and Merck and Co, Inc. (Updated on April 20, 2022)
Reviewer 3 has no relevant financial relationships with ineligible companies to disclose. (Updated on July 27, 2022)
Dr Hirsch has no relevant financial relationships with ineligible companies to disclose. (Updated on April 27, 2022)
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Independent educational grants for the 2022 Improving the Management of HIV Disease® CME program:
PLATINUM SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare
SILVER SUPPORTER
Janssen Therapeutics
BRONZE SUPPORTER
Theratechonologies Inc
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.
Contact Information
If you have any questions about this activity, please contact the IAS–USA:
Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.